ライフサイエンスコーパス: DAPT

1 DAPT (aspirin and clopidogrel) for 24 versus 6 months.

2 DAPT cessation modes included physician-recommended disc

3 DAPT continuation beyond 1 year showed no effects on mor

4 DAPT disruption was associated with a higher risk of MAC

5 DAPT duration was categorised in each study as shorter v

6 DAPT duration was on the basis of patient characteristic

7 DAPT interruption and disruption were significantly more

8 DAPT is indicated to lower the risk of ischemic events,

9 DAPT prevented such increase in MILD, PWV and MEAD (P <

10 DAPT scores >/=2 were associated with reductions in MI/s

11 DAPT treatment reduced lung cell apoptosis and attenuate

12 DAPT was associated with reduced stroke risk in TIA pati

13 884 patients (44.9%) had a DAPT score of at least 2, and 1086 (55.1%) had a score l

14 Only 2 ST events occurred after DAPT discontinuation between 30 and 90 days (both betwee

15 Among DAPT Study patients (derivation cohort; mean age, 61.3 y

16 eatment with CHIR99021, a Wnt activator, and DAPT, a Notch inhibitor, leads to further enhanced contr

17 p = 0.74) were observed between aspirin- and DAPT-treated patients, respectively.

18 own signaling regulators (e.g., butyrate and DAPT) produced measurable and predictable effects on the

19 Both GI254023X and DAPT reduced the production of CD44-ICD upon CTS loading

20 one, aspirin only, P2Y12 inhibitor only, and DAPT).

21 performances of the PRECISE-DAPT, PARIS, and DAPT (bleeding component) bleeding risk scores in the me

22 The PRECISE-DAPT, PARIS, and DAPT (bleeding component) risk scores were applied in th

23 ces (95% CI) of the PRECISE-DAPT, PARIS, and DAPT (bleeding component) scores through 12 months were

24 performances of the PRECISE-DAPT, PARIS, and DAPT (bleeding component) scores were reasonable and sim

25 ss and safety of concomitant use of PPIs and DAPT in the postdischarge treatment of unstable angina/n

26 By propensity and DAPT usage-adjusted multivariable analysis, permanent DA

27 One-month clear was defined as DAPT adherence and without major adverse events during t

28 poses a significant clinical dilemma because DAPT interruption exposes patients to the potential risk

29 mong HBR patients who were event free before DAPT discontinuation at 1 month, favorable safety and ef

30 the 5-year primary composite outcome between DAPT- and aspirin-treated patients (12.6% vs. 16.0%; adj

31 The relationship between DAPT and stroke was analyzed in a cox proportional hazar

32 e sought to examine the relationship between DAPT discontinuation and stent thrombosis (ST) after cob

33 ssed across randomized treatment arms and by DAPT score values <2 or >/=2.

34 e to AngII, were substantially diminished by DAPT.

35 mbryos, and inhibition of Notch signaling by DAPT partially rescued the apoptosis in zebrafish centra

36 n (PCI) bleeding that occurs on contemporary DAPT and its impact on quality of life (QOL).

37 Conversely, continuing DAPT may be associated with excess bleeding complication

38 of ticagrelor monotherapy over conventional DAPT.

39 ents randomized to prolonged or short-course DAPT after implantation of newer-generation DES and in s

40 h respect to mortality between the different DAPT strategies.

41 ssed within patients randomised to different DAPT durations (n=10 081) to identify the effect on blee

42 y and other clinical outcomes with different DAPT strategies.

43 quality evidence showed that longer-duration DAPT decreased risk for myocardial infarction (risk rati

44 major bleeding events than shorter-duration DAPT.

45 rediction of out-of-hospital bleeding during DAPT.

46 sk of clinical outcomes associated with each DAPT cessation mode.

47 yl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT) significantly rescued Tat-impaired NPC differentia

48 yl)-L-alanyl]-S-phenylglucine t-butyl ester (DAPT), a gamma-secretase inhibitor, which inhibits Notch

49 )-L-alanyl]-(S)-phenylglycine t-butyl ester; DAPT) was administered subcutaneously three times a week

50 The authors have evaluated DAPT utilization rates and associated outcomes among pos

51 Extended DAPT is associated with approximately 8 fewer myocardial

52 Extended DAPT was associated with a reduction in the risk of myoc

53 In this meta-analysis, extended DAPT beyond 1 year prevented myocardial infarctions and

54 Compared with 1-year DAPT, extended DAPT did not affect all-cause mortality (odds ratio [OR]

55 tervals, 0.89-3.09) associated with extended DAPT.

56 e first 12 months, the benefits of extending DAPT were similar in subjects with and without complex l

57 actors were associated with the decision for DAPT versus single antiplatelet therapy, and further stu

58 paclitaxel-eluting stent patient subset from DAPT through reductions in MI and stent thrombosis.

59 Furthermore, DAPT prevented glomerular basement membrane thickening a

60 Physician-guided DAPT discontinuation was not associated with increased r

61 cessations were defined as physician-guided DAPT discontinuation, brief interruption (<14 days) or d

62 A high DAPT score identified those experiencing the most benefi

63 Although higher DAPT scores identify patients with greater absolute isch

64 organoids incubated with the Notch inhibitor DAPT, intestine tissues from mice given injections of th

65 h could be reversed with the Notch inhibitor DAPT.

66 NOTCH1 inhibitor DAPT (GSI-IX) significantly reduces CSCs population and

67 ition of Notch1 by gamma-secretase inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenyl g

68 ctivation with the gamma-secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylgl

69 Using gamma-secretase inhibitor DAPT to acutely block canonical Notch signaling, we iden

70 lizes BMP4 and the gamma-secretase inhibitor DAPT to induce SE differentiation from human induced plu

71 iation such as the gamma-secretase inhibitor DAPT.

72 r (GI254023X) and gamma-secretase inhibitor (DAPT) were used to inhibit CD44 cleavage.

73 nt of chondrocytes with the Notch inhibitor, DAPT, decreased both endogenous and BMP2-induced SMAD 1/

74 reatment with the gamma-secretase inhibitor, DAPT, to inhibit cleavage and release of Notch Intracell

75 comes for 2191 TL-PAS patients enrolled into DAPT were assessed.

76 ure, and longer dual antiplatelet therapy (L-DAPT) was defined as the per-protocol period of more pro

77 ause mortality was numerically higher with L-DAPT without reaching statistical significance.

78 Compared with L-DAPT, S-DAPT had an overall higher rate of stent thrombo

79 er rates of stent thrombosis compared with L-DAPT; the latter effect was significantly attenuated wit

80 A longer DAPT duration significantly increased bleeding in patien

81 wer all-cause mortality compared with longer DAPT (HR 0.82, 95% CI 0.69-0.98; p=0.02; number needed t

82 mortality with shorter compared with longer DAPT was attributable to lower non-cardiac mortality (0.

83 d DAPT resulted in harm in patients with low DAPT scores undergoing PCI but reduced risk for ischemic

84 mmendations, various strategies for managing DAPT during the perioperative period have been proposed.

85 Median DAPT duration was 32 days (interquartile range [IQR]: 30

86 ive risk, 0.68 [95% CI, 0.54-0.87]), midterm DAPT (absolute risk difference, -4.6 incident cases per

87 erm ticagrelor monotherapy following 1-month DAPT can favorably balance ischemic and bleeding risks i

88 mine the safety and effectiveness of 1-month DAPT duration following percutaneous coronary interventi

89 ting the safety and effectiveness of 1-month DAPT followed by single antiplatelet therapy in HBR pati

90 Ticagrelor monotherapy after 1-month DAPT was noninferior, but not superior, to conventional

91 rdial infarction in comparison with 12-month DAPT (absolute risk difference, -3.8 incident cases per

92 herapy) versus a reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) according

93 agrelor monotherapy or conventional 12-month DAPT followed by 12-month aspirin.

94 ronary intervention to conventional 12-month DAPT followed by aspirin monotherapy in the reduction of

95 duction, compared with conventional 12-month DAPT in time-to-first-event analysis (hazard ratio, 0.94

96 e, extended-term in comparison with 12-month DAPT was associated with a reduced risk of myocardial in

97 In comparison with 12-month DAPT, no significant differences in the risks of ischemi

98 s suggests that, in comparison with 12-month DAPT, short-term DAPT followed by P2Y12 inhibitor monoth

99 onotherapy; midterm (6-month) DAPT; 12-month DAPT; and extended-term (>12-month) DAPT after percutane

100 ly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin r

101 rity was demonstrated for 6- versus 24-month DAPT, with an absolute risk difference of 0.11% (95% con

102 istance to aspirin to receive 6- or 24-month DAPT.

103 ary efficacy outcome with 24- versus 6-month DAPT was greater in patients with high scores (risk diff

104 imary safety outcome with 24- versus 6-month DAPT was greater in patients with low scores (RD for sco

105 12-month DAPT; and extended-term (>12-month) DAPT after percutaneous coronary intervention with drug-

106 We compared short-term (<6-month) DAPT followed by aspirin or P2Y12 inhibitor monotherapy;

107 Y12 inhibitor monotherapy; midterm (6-month) DAPT; 12-month DAPT; and extended-term (>12-month) DAPT

108 ubjects were prespecified to a 1 or 6 months DAPT duration and received at least one dose of study dr

109 Of note, DAPT disruption occurred in 17.7%, 10.4%, and 7.8% at 1

110 Histologically, the aortae of DAPT-treated Apoe(-/-) mice had significant reduction in

111 Retrospective assessment of DAPT score-guided treatment duration in a randomized cli

112 Physician-guided discontinuation of DAPT appears to be safe, irrespective of HBR.

113 Disruption of DAPT is associated with an increased risk of major adver

114 fied according to a prespecified duration of DAPT (1, 6, or 12 months).

115 s after BMS, and the appropriate duration of DAPT after BMS is unknown.

116 ined as the per-protocol minimum duration of DAPT after the procedure, and longer dual antiplatelet t

117 stratification to a prespecified duration of DAPT of 1, 6, or 12 months (group 2); or the reference a

118 estions: Q1) What is the minimum duration of DAPT required after DES implantation?

119 alanced, decisions regarding the duration of DAPT therapy must take into account patients' values and

120 re also similar by SYNTAX score, duration of DAPT therapy, completeness of revascularization, and in

121 ecisions surrounding the optimal duration of DAPT.

122 ed trials that tested different durations of DAPT after DES implantation: shorter dual antiplatelet t

123 Q3) What is the clinical effect of DAPT in stable patients who are >1 year past an MI?

124 To evaluate the safety and efficacy of DAPT duration according to DAPT score.

125 The cumulative incidence of DAPT cessation was higher in HBR patients, mostly driven

126 , patterns, and association between modes of DAPT cessation and outcomes across bleeding risk groups.

127 Modes of DAPT cessations were defined as physician-guided DAPT di

128 ts taking aspirin who completed 12 months of DAPT without bleeding or ischemic events after receiving

129 time of lower extremity PVI, prescription of DAPT following intervention is ~50%.

130 12 months increases MI hazard regardless of DAPT score group.

131 imilarly, questions remain about the role of DAPT in long-term therapy of stable post-myocardial infa

132 y was to evaluate the efficacy and safety of DAPT after DES implantation.

133 CT of 15 603 patients to answer: A3): Use of DAPT >1 year after MI reduced the composite risk of card

134 y newer-generation DES to answer: A1) Use of DAPT for 12 months, as compared with use for 3 to 6 mont

135 A2) Use of DAPT for 18 to 48 months, compared with use for 6 to 12

136 The use of DAPT in patients with diabetes post-CABG in our cohort w

137 d-generation stents, and off-protocol use of DAPT in some studies.

138 ing outcomes, suggesting that routine use of DAPT may not be clinically warranted.

139 Early use of DAPT reduced stroke risk in TIA patients with positive D

140 included for analysis, with 49% initiated on DAPT post-PVI.

141 not already receiving anticoagulation or on DAPT at the time of lower extremity PVI, prescription of

142 Participants not on anticoagulation or DAPT before the procedure were considered for the final

143 of bleeding compared with the use of OAC or DAPT alone.

144 higher risk of major bleeding than all other DAPT groups.

145 e-adjusted multivariable analysis, permanent DAPT discontinuation before 30 days was independently as

146 days), and the association between permanent DAPT discontinuation and ST during this period is unclea

147 In this large pooled experience, permanent DAPT discontinuation before 30 days after cobalt chromiu

148 6.8 [8.4-85.4]; P<0.0001), whereas permanent DAPT discontinuation in any interval after 90 days was n

149 ard therapy with a vitamin K antagonist plus DAPT for 1, 6, or 12 months.

150 erapy or 2.5 mg rivaroxaban twice daily plus DAPT was associated with a reduced risk of all-cause mor

151 w-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months (group 2), or standard thera

152 usted vitamin K antagonist (once daily) plus DAPT for 1, 6, or 12 months (group 3).

153 12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleeding and thereby have a favorable

154 12 months or very-low-dose rivaroxaban plus DAPT for 1, 6, or 12 months was associated with a lower

155 ents compared with standard-of-care VKA plus DAPT.

156 py (DAPT; Group 2, n=709); and warfarin plus DAPT (Group 3, n=706).

157 The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, whit

158 INTERPRETATION: The PRECISE-DAPT score is a simple five-item risk score, which provi

159 and compare the performances of the PRECISE-DAPT, PARIS, and DAPT (bleeding component) bleeding risk

160 The PRECISE-DAPT, PARIS, and DAPT (bleeding component) risk scores w

161 The c-indices (95% CI) of the PRECISE-DAPT, PARIS, and DAPT (bleeding component) scores throug

162 d with DAPT, the performances of the PRECISE-DAPT, PARIS, and DAPT (bleeding component) scores were r

163 After the prespecified DAPT duration, subjects in Group 2 were switched to riva

164 Prolonged DAPT lowers the risk of ischemic events with no apparent

165 Prolonged DAPT resulted in harm in patients with low DAPT scores u

166 e <2) or benefit (score >/=2) from prolonged DAPT after percutaneous coronary intervention (PCI).

167 as the per-protocol period of more prolonged DAPT.

168 patients with PAD (5.2%) receiving prolonged DAPT relative to 8 (6.9%) of those receiving short DAPT

169 es moderately strong evidence that prolonged DAPT after implantation of newer-generation DES entails

170 cacy outcome varied by stent type; prolonged DAPT with high scores was effective only in patients rec

171 Whether prolonged DAPT benefits patients with high scores treated with con

172 idence of increased mortality with prolonged DAPT after DES implantation.

173 9) per 1000 patients treated with prolonged DAPT per year.

174 idence of increased mortality with prolonged DAPT.

175 Prolonging DAPT requires careful assessment of the trade-off betwee

176 ) What is the clinical benefit of prolonging DAPT up to 18 to 48 months?

177 ted with an increased likelihood of post-PVI DAPT prescription.

178 Among 11,648 randomized DAPT Study patients from 11 countries (August 2009-May 2

179 ays post-CABG, 544 (68.4%) patients received DAPT and 251 (31.6%) patients received aspirin alone.

180 sease) trial, we compared patients receiving DAPT (aspirin plus thienopyridine) and aspirin monothera

181 fficacy of PPI therapy in patients receiving DAPT in low- and high-dose aspirin subsets.

182 outcomes were similar for patients receiving DAPT versus aspirin monotherapy respectively, in subgrou

183 Physicians more frequently recommend DAPT discontinuation to anemic patients during the first

184 s undergo noncardiac surgery and may require DAPT interruption.

185 ients with coronary artery disease requiring DAPT, even if the patients are on low-dose aspirin.

186 S-DAPT had an overall significantly lower risk of CSB (OR:

187 S-DAPT had overall lower rates of bleeding yet higher rate

188 Compared with L-DAPT, S-DAPT had an overall higher rate of stent thrombosis (odd

189 tation: shorter dual antiplatelet therapy (S-DAPT) was defined as the per-protocol minimum duration o

190 all-cause mortality rate was observed with S-DAPT (OR: 0.87 [95% CI: 0.74 to 1.01]; p = 0.073).

191 elative to 8 (6.9%) of those receiving short DAPT (HR, 0.77; 95% CI, 0.27-2.21; P = .62), with a sign

192 ged group and 66.8 (11.3) years in the short DAPT group, and 667 (76.8%) were male in the prolonged g

193 nged group and 75.7 (8.7) years in the short DAPT group, and 97 (82.2%) were male in the prolonged gr

194 group and 655 (76.6%) were male in the short DAPT group.

195 group and 92 (71.9%) were male in the short DAPT group.

196 Prolonged vs short DAPT conveyed a lower risk of the primary efficacy end p

197 D treated with prolonged compared with short DAPT (HR, 0.07; 95% CI, 0-1.21; P = .01).

198 of an individualized strategy for shortened DAPT duration following percutaneous coronary interventi

199 Shorter DAPT was also associated with a lower risk of major blee

200 frequentist pairwise meta-analysis, shorter DAPT was associated with significantly lower all-cause m

201 is, patients treated with 6-month or shorter DAPT and 1-year DAPT had higher risk of myocardial infar

202 rm of dose-adjusted VKA daily with a similar DAPT stratification (group 3).

203 grel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus

204 (The Dual Antiplatelet Therapy Study [DAPT Study]; NCT00977938).

205 tics, combined with an abbreviated, tailored DAPT regimen, resulted in a lower risk of 1-year MACE in

206 h drug-eluting stents, whereas extended-term DAPT reduces myocardial infarction at the expense of mor

207 Conversely, extended-term DAPT was associated with a higher risk of major bleeding

208 median follow-up of 18 months, extended-term DAPT was associated with a reduced risk of myocardial in

209 tive risk, 0.61 [0.45-0.83]), and short-term DAPT followed by aspirin monotherapy (absolute risk diff

210 ing were observed with midterm or short-term DAPT followed by aspirin monotherapy, with the exception

211 in comparison with 12-month DAPT, short-term DAPT followed by P2Y12 inhibitor monotherapy reduces maj

212 otherapy, with the exception that short-term DAPT followed by P2Y12 inhibitor monotherapy was associa

213 More importantly, our results show that DAPT treatment blocks cytokine release and prevents glom

214 High-quality evidence showed that DAPT increased risk for major bleeding (RR, 1.63 [CI, 1.

215 The DAPT (Dual Antiplatelet Therapy) study enrolled patients

216 The DAPT (Dual Antiplatelet Therapy) Study, a double-blind t

217 The DAPT coprimary composite end point (death, myocardial in

218 The DAPT coprimary end point, stent thrombosis, was also low

219 The DAPT score improves prediction of patient benefit and ha

220 In the DAPT Study (Dual Antiplatelet Therapy), after percutaneo

221 In the DAPT Study, combined myocardial infarction (MI) or stent

222 Including the DAPT Study, we identified 14 eligible trials that random

223 timum duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent placement remain

224 timal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is unc

225 riate duration of dual-antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement remains c

226 timal duration of dual antiplatelet therapy (DAPT) after implantation of newer-generation drug-elutin

227 rsus 12 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) bas

228 llowing one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention to conven

229 timal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug

230 Although dual antiplatelet therapy (DAPT) beyond 1 year provides ischemic event protection a

231 tween patterns of dual antiplatelet therapy (DAPT) cessation and adverse events after percutaneous co

232 aseline anemia on dual antiplatelet therapy (DAPT) cessation patterns <=2 years after PCI and the sub

233 fits and harms of dual antiplatelet therapy (DAPT) continuation beyond 1 year after drug-eluting sten

234 dorsing shortened dual antiplatelet therapy (DAPT) duration in high bleeding risk (HBR) patients afte

235 ention to 1-month dual antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy or con

236 ents treated with dual antiplatelet therapy (DAPT) following percutaneous coronary intervention.

237 ing a benefit for dual antiplatelet therapy (DAPT) following peripheral vascular intervention (PVI),

238 bitors (PPIs) and dual antiplatelet therapy (DAPT) for cardiovascular outcomes.

239 ended duration of dual antiplatelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 month

240 nd post-operative dual antiplatelet therapy (DAPT) in patients who undergo coronary artery bypass gra

241 ort (</=6 months) dual antiplatelet therapy (DAPT) in patients with PAD undergoing PCI.

242 Dual antiplatelet therapy (DAPT) is prescribed to millions of patients worldwide fo

243 Prolonged dual antiplatelet therapy (DAPT) is recommended after an acute myocardial infarctio

244 Outcomes with dual antiplatelet therapy (DAPT) or triple therapy (DAPT plus warfarin) were compar

245 Dual antiplatelet therapy (DAPT) reduced stroke risk in high-risk transient ischemi

246 The dual-antiplatelet therapy (DAPT) score was developed to identify patients more like

247 ticipating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified analysis.

248 rom data from the Dual Antiplatelet Therapy (DAPT) Study, a multicenter trial involving 220 US and in

249 In the Dual Antiplatelet Therapy (DAPT) Study, continuation of dual antiplatelet therapy b

250 ents also receive dual antiplatelet therapy (DAPT) to reduce the risk of ischemic complications.

251 K antagonist plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and aspirin reduces the ris

252 Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischa

253 Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard a

254 gonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleedin

255 atients requiring dual antiplatelet therapy (DAPT).

256 ilar durations of dual-antiplatelet therapy (DAPT).

257 n 2.5 mg bid plus dual antiplatelet therapy (DAPT; Group 2, n=709); and warfarin plus DAPT (Group 3,

258 tiplatelet therapy (DAPT) or triple therapy (DAPT plus warfarin) were compared using Cox proportional

259 strategy (1-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versu

260 inite/probable ST were analyzed according to DAPT discontinuation in the following time intervals: 0

261 ty characteristics and compared according to DAPT score.

262 y and efficacy of DAPT duration according to DAPT score.

263 te/severe) events were compared according to DAPT score.

264 mortality and ischaemic events when added to DAPT, but caused increased bleeding.

265 essed the effect of omeprazole when added to DAPT; the other 30 (observational) assessed the effect o

266 Relative to DAPT, patients on triple therapy had a similar risk of M

267 sought to determine whether a decision tool (DAPT score) aids prescription of dual antiplatelet thera

268 Compared with uninterrupted DAPT, disruption, but not interruption and physician-rec

269 , 279 of whom were DWI positive and 281 used DAPT.

270 in patients used monotherapy than those used DAPT in TIA with positive DWI (23.7% vs. 13.4%, p = 0.02

271 nalysis may have been limited by the varying DAPT durations among studies.

272 Those receiving triple therapy versus DAPT had higher rates of major bleeding without a measur

273 eded to treat=10), and 41.9% in group 3 (VKA+DAPT).

274 Routine antiplatelet strategy was DAPT for 3 months post procedural.

275 ion was strongly associated with ST, whereas DAPT discontinuation beyond 90 days appeared safe.

276 he present study aims to investigate whether DAPT could reduce stroke risk in TIA with DWI positive.

277 ents in both HBR and non-HBR patients, while DAPT disruption was associated with an increased risk of

278 ormed to determine variables associated with DAPT initiation compared with those discharged on single

279 mpted to determine variables associated with DAPT prescription following lower extremity PVI.

280 -1.52]) were also positively associated with DAPT prescription.

281 iovascular outcomes when coadministered with DAPT.

282 Treatment of the LSCs with DAPT and SAHM1 reduced the proliferation rate and mainta

283 However, combining OAC with DAPT, a strategy also known as triple antithrombotic the

284 mooth muscle cells (vSMCs) was observed with DAPT (P < 0.01).

285 The Kaplan-Meier curves of TIA patients with DAPT and monotherapy were plotted.

286 Among patients with DAPT scores <2 in both groups, continued thienopyridine

287 During months 12 to 15, patients with DAPT scores <2 or >/=2 both had lower rates of MI with c

288 ubjects with anatomic complexity, those with DAPT scores >/=2 randomized to continued thienopyridine

289 A total of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspir

290 ortality compared with patients treated with DAPT for longer than 1 year.

291 eding risk in patients with ACS treated with DAPT without revascularization and help support shared d

292 cally managed patients with ACS treated with DAPT, the performances of the PRECISE-DAPT, PARIS, and D

293 cally managed patients with ACS treated with DAPT.

294 Although treatment with DAPT beyond 1 year after drug-eluting stent implantation

295 mpared longer than 1-year DAPT versus 1-year DAPT after drug-eluting stenting.

296 ated with 6-month or shorter DAPT and 1-year DAPT had higher risk of myocardial infarction and stent

297 g stent implantation as compared with 1-year DAPT remain controversial.

298 ized trials that compared longer than 1-year DAPT versus 1-year DAPT after drug-eluting stenting.

299 Compared with 1-year DAPT, extended DAPT did not affect all-cause mortality (

300 5% to 8%, compared with conventional 1-year DAPT.